keyword
MENU ▼
Read by QxMD icon Read
search

Lung cancer review

keyword
https://www.readbyqxmd.com/read/29474858/molecular-targets-and-anti-cancer-potential-of-escin
#1
Dorothy H J Cheong, Frank Arfuso, Gautam Sethi, Lingzhi Wang, Kam Man Hui, Alan Prem Kumar, Thai Tran
Escin is a mixture of triterpenoid saponins extracted from the horse chestnut tree, Aesculus hippocastanum. Its potent anti-inflammatory and anti-odematous properties makes it a choice of therapy against chronic venous insufficiency and odema. More recently, escin is being actively investigated for its potential activity against diverse cancers. It exhibits anti-cancer effects in many cancer cell models including lung adenocarcinoma, hepatocellular carcinoma and leukemia. Escin also attenuates tumor growth and metastases in various in vivo models...
February 20, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29474558/phase-3-study-of-ceritinib-vs-chemotherapy-in-alk-rearranged-nsclc-patients-previously-treated-with-chemotherapy-and-crizotinib-ascend-5-japanese-subset
#2
Katsuyuki Kiura, Fumio Imamura, Hiroshi Kagamu, Shingo Matsumoto, Toyoaki Hida, Kazuhiko Nakagawa, Miyako Satouchi, Isamu Okamoto, Mitsuhiro Takenoyama, Yasuhito Fujisaka, Takayasu Kurata, Masayuki Ito, Kota Tokushige, Ben Hatano, Makoto Nishio
Background: In the global, Phase 3, ASCEND-5 study, ceritinib improved progression-free survival (PFS) vs chemotherapy in patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) who had previously progressed on crizotinib and platinum-based chemotherapy. Here, we report efficacy and safety in a subset of Japanese patients from the ASCEND-5 study. Methods: Patients with advanced ALK-rearranged NSCLC received oral ceritinib 750 mg/day or chemotherapy (intravenous pemetrexed 500 mg/m2 or docetaxel 75 mg/m2 [investigator's choice], every 21 days)...
February 21, 2018: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29473504/immunotherapy-in-non-small-cell-lung-cancer-biological-principles-and-future-opportunities
#3
M Ilie, J Benzaquen, V Hofman, S Lassalle, N Yazbeck, S Leroy, S Heeke, C Bence, B Mograbi, N Glaichenhaus, C H Marquette, P Hofman
Immunotherapy aims to amplify the anticancer immune response through reactivation of the lymphocytic response raised against several tumor neo-antigens. To obtain an effective immune response, this therapeutic approach requires that a number of immunological checkpoints be passed, such as the activation of excitatory costimulatory signals or the avoidance of coinhibitory molecules. Among the immune checkpoints, the interaction of the membrane-bound ligand PD-1 and its receptor PD-L1 has received much attention because of remarkable efficacy in numerous clinical trials for various cancer types, including non-small cell lung cancer (NSCLC)...
February 21, 2018: Current Molecular Medicine
https://www.readbyqxmd.com/read/29473494/protein-tyrosine-nitration-in-lung-cancer-current-research-status-and-future-perspectives
#4
Xianquan Zhan, Yuda Huang, Shehua Qian
Oxidative/nitrative damage is a crucial element among the complex factors that contribute to lung carcinogenesis. Nitric oxide (NO) free radicals, through chemical modifications such as tyrosine nitration, are significantly involved in lung cancinogenesis and metastasis. NO-mediated protein nitration, which is the addition of the nitro group (-NO2) to position 3 of the phenolic ring of a tyrosine residue, is an important molecular event in lung cancer, and has been studied with mass spectrometry. Nitration is involved in multiple biological processes, including signal transduction, protein degradation, energy metabolism, mitochondrial dysfunction, enzyme inactivation, immunogenic response, apoptosis, and cell death...
February 21, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29473469/immunotherapy-for-thoracic-oncology-gone-viral
#5
Manish R Patel
Immune therapy has now been incorporated into the standard of care for non-small-cell lung cancer based on randomized trials showing superiority of anti-PD1 antibodies compared with chemotherapy. Thus there is a renewed interest in immune approaches to treating lung cancer. One promising approach is with oncolytic viruses that either naturally or through engineering, preferentially infect or kill cancer cells. In preclinical models of different thoracic cancers, it has been found that these viruses can induce immune responses through multiple mechanisms...
April 2018: Immunotherapy
https://www.readbyqxmd.com/read/29473436/nivolumab-in-the-treatment-of-microsatellite-instability-high-metastatic-colorectal-cancer
#6
Amir Mehrvarz Sarshekeh, Michael J Overman, Scott Kopetz
Nivolumab is a PD-1 inhibitor approved for the use in treatment of multiple tumor types (such as melanoma, non-small-cell lung cancer, renal cell carcinoma, urothelial cancer and Hodgkin's lymphoma). In July 2017, the US FDA granted accelerated approval of this agent for the treatment of metastatic colorectal cancer patients whose tumor harbors deficient mismatch repair, or microsatellite-instability high and have progressed on conventional chemotherapy. In this review, we will discuss the use, efficacy, and safety of this agent in microsatellite-instability high metastatic colorectal cancer...
February 23, 2018: Future Oncology
https://www.readbyqxmd.com/read/29472527/hints-on-atgl-implications-in-cancer-beyond-bioenergetic-clues
#7
REVIEW
Rolando Vegliante, Luca Di Leo, Fabio Ciccarone, Maria Rosa Ciriolo
Among metabolic rearrangements occurring in cancer cells, lipid metabolism alteration has become a hallmark, aimed at sustaining accelerated proliferation. In particular, fatty acids (FAs) are dramatically required by cancer cells as signalling molecules and membrane building blocks, beyond bioenergetics. Along with de novo biosynthesis, free FAs derive from dietary sources or from intracellular lipid droplets, which represent the storage of triacylglycerols (TAGs). Adipose triglyceride lipase (ATGL) is the rate-limiting enzyme of lipolysis, catalysing the first step of intracellular TAGs hydrolysis in several tissues...
February 22, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29471699/atezolizumab-for-the-treatment-of-colorectal-cancer-the-latest-evidence-and-clinical-potential
#8
Gonzalo Tapia Rico, Timothy J Price
Atezolizumab is a fully humanized, engineered monoclonal antibody (MAb) of IgG1 isotype that specifically targets programmed death ligand 1 (PD-L1), a key molecule in the cancer-immunity pathway. Atezolizumab is currently approved for the treatment of metastatic non-small-cell lung cancer (NSCLC) and advanced urothelial carcinomas. Areas covered: In this review, we will present the available (early phase clinical trials) data supporting the efficacy of atezolizumab for the treatment of metastatic colorectal cancer (mCRC)...
February 23, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29470536/metastatic-site-as-a-predictor-of-nivolumab-efficacy-in-patients-with-advanced-non-small-cell-lung-cancer-a-retrospective-multicenter-trial
#9
Motohiro Tamiya, Akihiro Tamiya, Takako Inoue, Madoka Kimura, Kei Kunimasa, Kenji Nakahama, Yoshihiko Taniguchi, Takayuki Shiroyama, Shun-Ichi Isa, Kazumi Nishino, Toru Kumagai, Hidekazu Suzuki, Tomonori Hirashima, Shinji Atagi, Fumio Imamura
PURPOSE: To conduct a retrospective multicenter trial to determine the significance of metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer. METHODS: This study was conducted across three medical centers in Japan. We retrospectively reviewed all patients who commenced nivolumab treatment at these centers between December 17, 2015 and July 31, 2016. Clinical data were collected, including age, sex, smoking status, Eastern Cooperative Oncology Group performance status, and metastatic site (lymph nodes, liver, brain, bone, lungs [intrapulmonary metastasis], and malignant pleural effusion) at the time of commencing nivolumab treatment...
2018: PloS One
https://www.readbyqxmd.com/read/29467888/characteristics-of-breast-metastases-from-non-breast-solid-tumors-in-22-patients-from-a-southern-chinese-population
#10
Peng Sun, Jiewei Chen, Jiabin Lu, Rongzhen Luo, Mei Li, Jiehua He
Breast metastases from solid non-breast tumor types are rare; however, they should be always considered in the differential diagnosis of a breast lesion owing to the associated poor patient prognosis and the requirement of different therapeutic strategies compared with those used to treat primary breast cancer. The aim of the current study was to summarize the characteristics of metastases to the breast in a southern Chinese population. The medical records and pathological sections of 22 patients with pathologically confirmed extra-mammary metastases to the breast that presented to Sun Yat-sen University Cancer Center between January 2000 and December 2015 were retrospectively reviewed...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29467866/notch-signaling-and-non-small-cell-lung-cancer
#11
Bin Zou, Xue-Liang Zhou, Song-Qing Lai, Ji-Chun Liu
Lung cancer is the leading cause of cancer-associated mortality worldwide. Elucidation of the pathogenesis and biology of lung cancer is critical for the design of an effective treatment for patients. Non-small cell lung cancer (NSCLC) accounts for 80-85% of lung cancer cases. The abnormal expression of Notch signaling pathway members is a relatively frequent event in NSCLC. The Notch signaling pathway serves important roles in cell fate determination, proliferation, differentiation and apoptosis. Increasing evidence supports the association of Notch signaling dysregulation with various types of malignant tumor, including NSCLC...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29467147/alectinib-for-advanced-alk-positive-non-small-cell-lung-cancer
#12
REVIEW
Ashley C Ly, Jacqueline L Olin, Morgan B Smith
PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, safety and tolerability, dosage and administration, and place in therapy of alectinib for treatment of patients with non-small-cell lung cancer (NSCLC) are reviewed. SUMMARY: In patients with NSCLC driven by mutations of ALK , the gene coding for anaplastic lymphoma kinase (ALK), treatment with the ALK inhibitor crizotinib has been found to provide median progression-free survival (PFS) of 10.9 months; however, therapeutic failures and tumor progression to brain metastases are common with crizotinib use, prompting research to find more potent and tolerable ALK inhibitors that target major oncogenic drivers of NSCLC...
February 21, 2018: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/29466887/access-to-anti-cancer-drugs-in-india-is-there-a-need-to-revise-reimbursement-policies
#13
Gertruud Haitsma, Himanshu Patel, Parthasarathi Gurumurthy, Maarten J Postma
BACKGROUND: The aim of this study was to examine the access of Indian cancer patients to optimum cancer care under selected government schemes by reviewing reimbursement schemes for cancer care in India. METHODS: All cancer care reimbursement schemes in India were identified and three highly utilized schemes (VAS, RAS, CMCHS) were selected. Quality of breast, colorectal, lung, head & neck, and gastric cancer care was reviewed with respect to NCCN guidelines...
February 22, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29465599/primary-pulmonary-lymphoepithelioma-like-carcinoma-in-non-endemic-region-a-case-report-and-literature-review
#14
Chao Xie, Xia Xu, Bian Wu, Kun-Yu Yang, Jing Huang
RATIONALE: Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare type of lung squamous cell carcinoma. In situ hybridization test for Epstein-Bar virus-encoded RNA (EBER) is generally used for distinguishing it from other lung cancers. Although plasma EBV DNA quantification has been widely used as a tumor biomarker in nasopharyngeal carcinoma (NPC), only a limiting number of studies have suggested that plasma EBV DNA quantification may be used as a tumor marker in pulmonary LELC patients...
February 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29465427/dihydrotestosterone-and-cancer-risk
#15
Yi X Chan, Bu B Yeap
PURPOSE OF REVIEW: Androgens have been implicated in prostate growth; however, the role of androgens in prostate cancer development is not clear. Furthermore, studies suggest a role for androgens in female-hormone-dependent cancers and common nonhormone dependent cancers. This study aims to review key studies and more recent studies of dihydrotestosterone (DHT) and cancer risk. RECENT FINDINGS: Epidemiological studies are reassuring as they have not associated endogenous androgens with prostate cancer risk...
February 19, 2018: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/29465366/cancer-development-in-korean-patients-with-anca-associated-vasculitis-a-single-centre-study
#16
Juyoung Yoo, Sung Soo Ahn, Seung Min Jung, Jason Jungsik Song, Yong-Beom Park, Sang-Won Lee
OBJECTIVES: We investigated the incidence rate and type of cancer, and furthermore, estimated the standardised incidence ratios (SIRs) of cancer in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in Korea. METHODS: We retrospectively included 150 patients with AAV [81 patients with microscopic polyangiitis (MPA), 38 with granulomatosis with polyangiitis (GPA) and 31 patients with eosinophilic GPA (EGPA)], and reviewed their medical records...
February 14, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29464135/impact-of-cyberknife-radiosurgery-on-median-overall-survival-of-various-parameters-in-patients-with-1-12-brain-metastases
#17
Judith Murovic, Victoria Ding, Summer S Han, John R Adler, Steven D Chang
Introduction This study's objective is to assess various patient, tumor and imaging characteristics and to compare median overall survival (OS) of 150 patients with 1-12 brain metastases post-CyberKnife radiosurgery (CKRS) (Accuray, Sunnyvale, California) alone. Methods Charts of 150 patients, from 2009-2014, treated with only CKRS for brain metastases were reviewed retrospectively for patient, tumor, and imaging characteristics. Parameters included demographics, Eastern Cooperative Oncology Group (ECOG) performance scores, number and control of extracranial disease (ECD) sites, cause of death (COD), histology, tumor volume (TV), and post-CKRS whole brain radiotherapy (WBRT)...
December 8, 2017: Curēus
https://www.readbyqxmd.com/read/29464099/implications-of-kras-mutations-in-acquired-resistance-to-treatment-in-nsclc
#18
REVIEW
Marzia Del Re, Eleonora Rofi, Giuliana Restante, Stefania Crucitta, Elena Arrigoni, Stefano Fogli, Massimo Di Maio, Iacopo Petrini, Romano Danesi
Rationale: KRAS is the most common and, simultaneously, the most ambiguous oncogene implicated in human cancer. Despite KRAS mutations were identified in Non Small Cell Lung Cancers (NSCLCs) more than 20 years ago, selective and specific inhibitors aimed at directly abrogating KRAS activity are not yet available. Nevertheless, many therapeutic approaches have been developed potentially useful to treat NSCLC patients mutated for KRAS and refractory to both standard chemotherapy and targeted therapies...
January 19, 2018: Oncotarget
https://www.readbyqxmd.com/read/29463588/pathways-and-cost-effectiveness-of-routine-lung-cancer-inpatient-care-in-rural-anhui-china-a-retrospective-cohort-study-protocol
#19
XingRong Shen, MengJie Diao, ManMan Lu, Rui Feng, PanPan Zhang, Tao Jiang, DeBin Wang
INTRODUCTION: Routine inpatient care (RIC) for patients with cancer forms various pathways of clinical procedures. Although most individual procedures comprising the pathways have been tested via clinical trials, little is known about the collective cost and effectiveness of the pathways as a whole. This study aims at exploring RIC pathways for patients with lung cancer from rural Anhui, China, and their determinants and economic impacts. METHODS AND ANALYSIS: The study adopts a retrospective cohort design and proceeds in five steps...
February 20, 2018: BMJ Open
https://www.readbyqxmd.com/read/29463190/cyfra-21-1-predicts-the-efficacy-of-nivolumab-in-patients-with-advanced-lung-adenocarcinoma
#20
Hiromichi Shirasu, Akira Ono, Katsuhiro Omae, Kazuhisa Nakashima, Shota Omori, Kazushige Wakuda, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Masahiro Endo, Takashi Nakajima, Toshiaki Takahashi
CYFRA 21-1 is a prognostic marker for non-small cell lung cancer. The serum CYFRA 21-1 level is also known as an adjunct for the diagnosis of lung squamous cell carcinoma. This study aimed to examine whether CYFRA 21-1 has predictive implications for nivolumab therapy in patients with advanced lung adenocarcinoma. Of the 79 patients who were treated with nivolumab therapy at the Shizuoka Cancer Center between December 2015 and September 2016, we retrospectively reviewed the data of 50 patients. The patient characteristics were as follows: age <70/≥70 years: 43 (86%)/7; male/female: 31 (62...
February 2018: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
keyword
keyword
15799
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"